Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

 Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis for its CDZ173 to Treat Activated Phosphoinositide 3-kinase Delta Syndrome


  • Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option
  • In 2017, Novartis signed an option agreement with Akcea for two antisense therapies AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular disease. In Feb 2019 Novartis exercised its option for AKCEA-APO(a)-LRx due to strategic portfolio reason , further decided not to exercise option for second therapy i.e. AKCEA-APOCIII-LRx
  • AKCEA-APOCIII-LRx is ligand conjugated antisense (LICA) drug co-developed by Akcea and Ionis using ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform and is currently in P-II for patients with hypertriglyceridemia and CVD with expected results in H1’20

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post